The disposal for Supermarket Retail for $13.5m is in line with the company’s stated strategy following its recent strategic review, the results of which were announced in Feb 2016. The main use of proceeds will be to progress development of immuno-modulatory therapeutics in dermatology and ophthalmology, leveraging the significant IP and know-how accumulated by the company in relation to the use and formulations of hypochlorous acid. The first two IND filings are planned for Q1 2017. We view tod ....
20 Sep 2016
N+1 Singer - PuriCore - Disposal of Supermarket Retail
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - PuriCore - Disposal of Supermarket Retail
Realm Therapeutics (RLM:LON) | 0 0 0.3% | Mkt Cap: 57.1m
- Published:
20 Sep 2016 -
Author:
Dr Jens Lindqvist -
Pages:
3
The disposal for Supermarket Retail for $13.5m is in line with the company’s stated strategy following its recent strategic review, the results of which were announced in Feb 2016. The main use of proceeds will be to progress development of immuno-modulatory therapeutics in dermatology and ophthalmology, leveraging the significant IP and know-how accumulated by the company in relation to the use and formulations of hypochlorous acid. The first two IND filings are planned for Q1 2017. We view tod ....